Article

Uromonitor®: Clinical Validation and Performance Assessment of a Urinary Biomarker for Recurrence Surveillance in Non-Muscle Invasive Bladder Cancer Patients

2023-11-03

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Introduction</h4> Bladder cancer (BC) remains the most common malignancy of the urinary tract, with non-muscle invasive BC (NMIBC) representing the vast majority of bladder cancer patients. The current standard of care (SOC) follow-up in NMIBC patients demands an intensive schedule and requires costly and burdensome methods, driving the development of alternative, non-invasive, cost-effecti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 711bab36-08d1-5013-9279-96479807e9e0
DOI: 10.1101/2023.11.02.23297958

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Uromonitor®: Clinical Validation and Performance Assessment of a Urinary Biomarker for Recurrence Surveillance in Non-Muscle Invasive Bladder Cancer PatientsDOI 10.1101/2023.11.02.23297958Read

Uromonitor: Clinical Validation and Performance Assessment of a Urinary Biomarker Within the Surveillance of Patients With Nonmuscle-Invasive Bladder Cancer.Semantic proximity Read

Diagnostic Test Accuracy of Commercially Available Tests for The Recurrence of Bladder Cancer: A Systematic Review and Meta-AnalysisSemantic proximity Read

Urinary Biomarkers in Urothelial Carcinoma: Expanded Con-temporary Evidence for Diagnosis, Surveillance, Risk Stratification, and Cystoscopy-Sparing Clinical PathwaysSemantic proximity Read

Uromonitor <sup>®</sup> as a novel sensitive and specific urine-based test for recurrence surveillance of patients with non-muscle invasive bladder cancerSemantic proximity Read

Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence.Semantic proximity Read

Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and SurveillanceSemantic proximity Read

Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter StudySemantic proximity Read

A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.Semantic proximity Read

GALEAS™ Bladder Demonstrates High Sensitivity and Specificity for Detecting Bladder Cancer: Real-World Multicentre Data from UK NHS Haematuria ClinicsSemantic proximity Read

Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?Semantic proximity Read

Real-world performance of Uromonitor® in urothelial bladder cancer detection: a multicentric trial.Semantic proximity Read

Biomarkers of Bladder Cancer: Cell-Free DNA, Epigenetic Modifications and Non-Coding RNAsSemantic proximity Read